Giannis Mountzios, Director of the 4th Oncology Department and Clinical Trials Unit at Henry Dunant Hospital Center, shared a post on LinkedIn:
“How do we combine TKIs with various forms of radiotherapy in NSCLC? When should we interrupt or modify their dose?
Just out in ESMO Open Journal a collaborative effort between ESMO – European Society for Medical Oncology and European Society for Radiotherapy and Oncology (ESTRO) with recommendations for EGFR, ALK and BRAF/MEK inhinitors.
Happy to have contributed to this practical guide for clinicians!”
Title: ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitors
Authors: E.S.M. van Aken, S.M. O’Cathail, A.K. Gandhi, J. Bussink, L. Castelo-Branco, J.G. Eriksen, G. Argilés, C.T. Hiley, V. Atkinson, J. Kaźmierska, A. Calles, K. Konopa, E. Le Rhun, F. McDonald, G. Mountzios, P.M. Putora, B. Muoio, U. Ricardi, C.B. Westphalen, A. Wrona, A. Prelaj
Read the Full Article.
Other articles featuring Giannis Mountzios on OncoDaily.